Pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in adults

Current Psychiatry Reviews

Volumn 2, Issue 3, 2006, Pages 317-331

  Dowson, Jonathan H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adult; Attention deficit; Hyperactivity; Impulsivity; Treatment

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DISULFIRAM; FLUOXETINE; GUANETHIDINE; GUANFACINE; IMIPRAMINE; LITHIUM SALT; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NORTRIPTYLINE; PARGYLINE; PEMOLINE; PLACEBO; PROPRANOLOL; RISPERIDONE; SALBUTAMOL; SELEGILINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANXIETY; APPETITE DISORDER; ARTHRALGIA; ATTENTION DEFICIT DISORDER; BLOOD DISEASE; BODY WEIGHT DISORDER; BRAIN DYSFUNCTION; BRAIN HEMORRHAGE; CARDIOMYOPATHY; CHOREA; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONSTIPATION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DYSKINESIA; DYSMENORRHEA; DYSPHORIA; ERYTHEMA MULTIFORME; EUPHORIA; EXERCISE; EXFOLIATIVE DERMATITIS; FATIGUE; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERMETABOLISM; HYPERTENSION; HYPERTENSIVE CRISIS; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; META ANALYSIS; NAUSEA; NEUROLOGIC EXAMINATION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT REFERRAL; PREVALENCE; PRIAPISM; PRIORITY JOURNAL; PRURITUS; PSYCHIATRIST; RESTLESSNESS; REVIEW; SEDATION; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SUBSTANCE ABUSE; SYMPTOM; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TIC; TREMOR; URINARY TRACT DISEASE; URINE RETENTION; URTICARIA; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33747637173     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340006778018157     Document Type: Review

References (214)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington DC, Am Psychiatr Press 1994.
2. Barbaresi WJ, Katusic SK, Culligan RC, et al. How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. Arch Paediatr Adolesc Med 2002; 156: 209-210.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder: DSM-IV-R. Washington DC, Am Psychiatr Press 2000.
4. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention-deficit/hyperactivity disorder: Impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816-818.
5. Sachdev P. Attention deficit hyperactivity disorder in adults. Psychol Med 1999; 29: 507-514.
6. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann of the N Y Acad of Sci 2001; 931: 1-16.
7. Levy F, Hay DA, McStephen M, Wood C, Waldman I. Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad Child Adolesc Psychiatry 1997; 36: 737-744.
8. Jick JH, Kaye JA, Black C. Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK. Br J Gen Pract 2004; 54: 345-347.
9. Timimi S, Taylor E. ADHD is best understood as a cultural constraint. Br J Psychiatry 2004; 184:8-9
10. Zivi M, Ramchandani P, Joughin C. Evidence and belief in ADHD. Br Med J 2000; 321:975.
11. Spencer T, Biederman J, Wilens TE, Faraone SV. Adults with Attention-Deficit/Hyperactivity Disorder: A Controversial Diagnosis. J Clin Psychiatry 1998; 59(suppl 7):59-68.
12. Faraone SV, Wilens T. Does stimulant treatment lead to substance-use disorders? J Clin Psychiatry 2003; 64(suppl 11): 9-13.
13. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollacks S. Clinical efficacy of methylphenidate in conduct disorders with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54: 1077-1080.
14. Weller EB, Rowan A, Elia J, Weller RA. Aggressive Behaviour in Patients with Attention-Deficit/Hyperactivity Disorder, Conduct Disorder And Pervasive Dev Disorders. J Clin Psychiatry 1999; 60 suppl 15:5-11.
15. Sokol S, Gray NS, Goldstein A, Kaye WH. Methylphenidate treatment for bulimia nervosa associated with Cluster B personality disorder. Int J Eat Disord 1999; 25: 233-237.
16. Willoughby MT, Curran PJ, Costello EJ, Angold A. Implications of early versus late onset of attention-deficit/hyperactivity disorder symptoms. J Am Acad Child Adolesc Psychiatry 2000; 39: 1512-1519.
17. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001; 40: 147-158.
18. Faraone SV, Biederman J, Monuteaux MC. Attention-deficit disorder and conduct disorder in girls: evidence for a familial subtype. Biol Psychiatry 2000; 48: 21-29.
19. Todd RD, Rasmussen ER, Neuman RJ, et al. Familiality and Heritability of Subtypes of Attention Deficit Hyperactive Disorder in a Population Sample of Adolescent Female Twins. Am J Psychiatry 2001; 158: 1891-1898.
20. Diamond A. Attention-deficit disorder...: A neurobiologically and behaviourally distinct disorder. Dev Psychopathol 2005; 17: 807-825.
21. Gershon J. A meta-analysis review of gender differences in ADHD. J Atten Disord 2002; 5:143-154.
22. Quinn PO. Treating adolescent girls and women with ADHD: Gender-Specific issues. J Clin Psychol 2005; 61: 579-587.
23. Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9:481-498.
24. Weiss G, Hechtman LT. Hyperactive Children Grown-up: ADHD in Children, Adolescents and Adults. 2nd edition. New York, The Guilford Press 1993.
25. Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9: 711-726.
26. Thapar A, Holmes J, Poulton K, Harrington R. Genetic basis of attention deficit and hyperactivity. Br J Psychiatry 1999; 174:105-111.
27. Roman T, Rohde LA, Hertz MH. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder. Am J Pharmacogenomics 2004; 4: 83-92.
28. Mill J, Fisher N, Curran S, Richards S, Taylor E, Asherson P. Polymorphisms in the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Neuroreport 2003; 14:1463-1466
29. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. Is maternal smoking during pregnancy a risk factor for Attention Deficit Hyperactivity Disorder in Children? Am J Psychiatry 1996; 153:1138-1142.
30. Burd L,Cotsonac-Hassler TM, Martsolf JT, Kerbeshian J. Recognition and management of fetal alcohol syndrome. Neurotoxicology and Teratology 2003; 25: 681-688.
31. Hanser P, Soler R, Brucker-Davis F, Weintroub BD. Thyroid hormones correlate with symptoms of hyperactivity but not inattention in attention deficit hyperactivity disorder. Psychoneuroendocrinology 1997; 22: 107-114.
32. Hauser P, McMillin JM, Bhatara VS. Resistance to thyroid hormone: implications for neurodevelopmental research on the effects of thyroid hormone disruption. Toxicol Ind Health 1998; 14: 85-101.
33. Waldman ID, Rhee SH, Levy F, Hay DA. Causes of the overlap among symptoms of Attention Deficit Hyperactivity Disorder, Oppositional Deficit Disorder, and Conduct Disorder. In: Attention, Genes and ADHD, Philadelphia PA, Brunner-Routledge 2001; 115-138.
34. Pliszka SR. Comorbidity of Attention-Deficit/Hyperactivity Disorder with Psychiatric Disorder: An Overview. J Clin Psychiatry 1998; 59 suppl 7: 50-58.
35. Rosler M, Retz W, Retz-Junginger P, et al. Prevalence of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 2004; 254: 365-371.
36. Flory K, Lynam DR. The relations between attention deficit hyper-activity disorder and substance abuse: what role does conduct disorder play? Clin Child Fam Psychol Rev 2003; 6: 1-16.
37. Fischer M, Barkley RA, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002; 30: 463-475.
38. Kent L and Craddock N. Is there a relationship between attention deficit hyperactivity disorder and bipolar disorder J Affect Disord 2003; 73: 211-221.
39. Wilens TE, Prince JB, Spencer T. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003; 54: 9-16.
40. Wilens TE, Biederman J, Wozniak J, Gunawardene S, Wong J, Monuteaux M. Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically-referred adults. Biol Psychiatry 2003; 54: 1-8.
41. Milberger S, Biederman J, Faraone SV, Murphy J, Tsuang MT. Attention Deficit Hyperactivity Disorder and Comorbid Disorders: Issues of Overlapping Symptoms. Am J Psychiatry 1995; 152: 1793-1799.
42. Harrington R and Myatt T. Is preadolescent mania the same condition as adult mania? A British perspective. Biol Psychiatry 2003; 53: 961-969.
43. Wagner KD. Diagnosis and treatment of bipolar disorder in children and adolescents. J Clin Psychiatry 2004; 65(Suppl 15):30-34.
44. Reich W, Neuman RJ, Volk HE, Joyner CA, Todd RD. Comorbidity between ADHD and symptoms of bipolar disorder in a community sample of children and adolescents. Twin Res Hum Genet 2005; 8: 459-466.
45. Faraone SV, Biederman J,Mennin D, Wozniak J, Spencer T. Attention-deficit hyperactivity disorder with bipolar disorder: a familial subtype? J of Am Acad Child Adolesc Psychiatry 1998; 37: 459-460.
46. Galanter CA, Carlson GA, Jensen PS et al. Response to methylphenidate in children with attention-deficit hyperactivity disorder and manic symptoms. J Child Adolesc Psychopharmacol 2003; 13: 123-136.
47. Spencer TJ, Biederman J, Wozniak J, Faraone SV, Wilens TE, Mick E. Parsing pediatric bipolar disorder from its associated comorbidity with the disruptive behaviour disorders. Biol Psychiatry 2001; 49: 1062-1070.
48. Hazell PL, Carr V, Lewin TJ, Sly K. Manic symptoms in young males with ADHD predict functioning but not diagnosis after 6 years. J Am Acad Child Adolesc Psychiatry 2003; 42: 552-560.
49. Sachs GS, Baldassano CF, Truman CJ, Guille C. Comorbidity of attention-deficit hyperactivity disorder with early- and late-onset bipolar disorder. Am J Psychiatry 2000; 157: 466-468.
50. Nierenberg AA, Miyahara S, Spencer T et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder. Biol Psychiatry 2005; 57: 1467-1473.
51. Greenwood TA, Schork NJ, Eskin E, Kelsoe JR. Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol Psychiatry 2005; E pub ahead of print.
52. Kessler RC, Adler L, Ames M, et al. The World Health Organisation adult ADHD self-report scale (ASRS).: a short screening scale for use in the general population. Psychol Med 2005; 35:245-256.
53. Barkley RA. Comorbid Disorders, Social Relations and Subtyping. Chapter 4. In: Attention-Deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment. New York, The Guilford Press. 1998; 139-163.
54. Murphy P, Schachar R. Use of Self-Ratings in the Assessment of Symptoms of Attention Deficit Hyperactivity Disorder in Adults. Am J Psychiatry 2000; 157:1156-1159.
55. Barkley RA, Murphy KR. Attention-deficit hyperactivity disorder. A clinical workbook. 2nd Edition. New York, The Guilford Press 1998.
56. Triolo SJ, Murphy KR. Attention-deficit scales for adults (ADSA). Manual for scoring and interpretation. New York,. Brunner/Maze Inc, 1996.
57. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS) New York, Multi-Health Systems Inc. 1999.
58. Brown TE. Brown Attention-Deficit Disorder Scales. New York, The Psychol Corporation, Harcourt Brace & Company, 1996.
59. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin N Am 2004; 27: 187-201.
60. Wilens TE, Spencer TJ, Biederman J. Pharmacotherapy of Adult ADHD. In: Attention-Deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment. New York, The Guilford Press, 1998, 592-603.
61. Steinhausen H-C. Attention-deficit hyperactivity disorder in a life perspective. Acta Psychiatra Scandinavica 2003; 107: 592-603.
62. Weiss MD and Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry 2004; 65(Suppl 3): 27-37.
63. Safren SA, Sprich S, Chulvick, Otto MW. Psychosocial treatments for adults with attention-deficit/hyperactivity disorder. Psychiatr Clin N Am 2004; 27: 349-360.
64. Stevenson CS, Whitmont S, Bornholt L, Livesey D, Stevenson RJ. A cognitive remediation programme for adults with Attention Deficit Hyperactivity Disorder. Aust N Z J Psychiatry 2002; 36: 610-616.
65. Carter CM, Urbanowicz M, Hemsley R, et al. Effects of a few food diet in attention deficit disorder. Arch Dis Child 1992; 69: 564-568.
66. Bradley C. The behaviour of children receiving benzedrine. Am J Psychiatry 1937; 577-585.
67. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9: 77-97.
68. Solanto MV, Arnsten AFT, Castellanos FX. The Neuroscience of Stimulant Drug Action in ADHD. In: Stimulant Drugs and ADHD. Eds. Solanto MV, Arnsten AFT, Castellanos FX. Oxford, Oxford University Press 2001; 355-379.
69. Elliott R, Sahakian BJ, Matthews K, Bannerjee A, Rimmer J, Robbins TW. Effects of Methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacol 1997; 131: 196-206.
70. Hazell P. Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder? Exp Opin Pharmacother 2005; 6: 1989-1998.
71. Challman TD, Lipsky JJ. Methylphenidate: Its Pharmacology and Uses. Mayo Clin Proc 2000; 75:711-721.
72. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 2002; 6(Suppl 1): 531-43.
73. Conners CK. Forty years of methylphenidate treatment in Attention-Deficit/Hyperactivity Disorder. J Atten Disord 2002; 6(Suppl 1): 517-30.
74. Grcevich S, Rowane WA, Marcellino B, Sullivan-Hurst S. Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11: 35-41.
75. Manos MJ, Short EJ, Findling RL. Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/ hyperactive disorder. J Am Acad child Adolesc Psychiatry 1999; 38: 813-819.
76. Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Managed Care 2004; 10(4 Suppl):S117-124.
77. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002; 22: 468-473.
78. Hazell P. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder. Australasian Psychiatry 2004; 12: 369-379.
79. Faraone SV, Short EJ, Biederman J, Findling RL, Roe C, Manos MJ. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. Int J Neuropsychopharmacology 2002; 5: 121-129.
80. Serra-Pinheiro MA, Mattos P, Souza I, Pastura G, Gomes F. The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. Arquiva Neuropsiquiatrica 2004; 62(2B); 399-402.
81. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord 2002; 5: 189-202.
82. Maidment ID. Efficacy of stimulants in adult ADHD. Ann Pharmacotherapy 2003; 37: 1884-1890.
83. Riggs PD, Hall SK, Mitzulich-Gilbertson SK, Lohman M, Kayser A. A randomized controlled trial of pemoline for attention-deficit/ hyperactivity disorder in substance-abusing adolescents. J Am Acad Child and Adolesc Psychiatry 2004; 43: 420-429.
84. Pataki CS, Feinberg DT, McGough JJ. New drugs for the treatment of attention-deficit/hyperactivity disorder. Exp Opin Emerg Drugs 2004; 9: 293-302.
85. Fone KC, Nutt DJ. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol 2005; 5: 87-93.
86. Jensen P. Longer-term effects of stimulant treatments for Attention-Deficit/Hyperactivity Disorder. J Atten Disord 2002; 6(Suppl 1): 545-56.
87. Arnold CE, Abiko HB, Cantwell DP et al. National Institute of Mental Health Collaborative Multimodel Treatment Study of Children with ADHD (the MTA). Arch Gen Psychiatry 1997; 54: 865-870.
88. The MTA Co-operative Group. A 14-month Randomised Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder. Arch Gen Psychiatry 1999; 56: 1073-1086.
89. The MTA Co-operative Group. National Institute of Mental Health Multimodel Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Paediatr 2004; 113: 754-761.
90. Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry 1976; 33: 1453-1460.
91. Wender PH, Reimherr FW, Wood D, Ward M. A Controlled Study of Methylphenidate in the Treatment of Attention Deficit Disorder, Residual Type, in Adults. Am J Psychiatry 1985: 547-552.
92. Spender T, Wilens, Biederman J, Faraone SV, Ablon JS, Lapey K. A Double-blind, Crossover Comparison of Methylphenidate and Placebo in Adults with Childhood-Onset Attention-Deficit Hyperactivity Disorder. Arch Gen Psychiatry 1995; 52: 434-443.
93. Wilens TE. Drug therapy for adults with attention-defect hyperactivity disorder. Drugs 2003; 63: 2395-2411.
94. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 2004; 24: 24-29.
95. Riordan HJ, Flashman LA, Saykin AJ, Frutiger SA, Carroll KE, Huey L. Neuropsychological correlates of methylphenidate treatment in adult ADHD with and without depression. Arch Clin Neuropsychol 1999; 14: 217-233.
96. Aron AR, Dowson JH, Sahakian BJ, Robbins TW. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2003; 54: 1465-1468.
97. Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ. Neurocognitive effects of methylphenidate in adult attention-deficit/ hyperactivity disorder. Psychopharmacol (Berl) 2005; 178: 286-295.
98. Cox DJ, Merkel RL, Kovatchev B, Seward R. Effect of Stimulant Medication on Driving Performance of Young Adults with Attention-Deficit Hyperactivity Disorder. J Nerv Ment Dis 2000; 188: 230-234.
99. Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK. Efficacy and safety of methylphenidate in 45 adults with attention deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med 2004; 34: 973-982.
100. Wolraich ML, Doffing MA. Pharmackinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 2004; 18: 243-250
101. Winsberg BG, Comings DE. Association of the dopamine transponder gene (DAT1) with patient methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999; 38: 1478-1481.
102. Gualtieri CT, Wargin W, Kanoy R, et al. Clinical Studies of Methylphenidate Serum Levels in Children and Adults. J Am Acad Child Psychiatry 1982; 21: 19-26
103. Sonuga-Barke EJ, Swanson JM, Coghill D, DeCory HH, Hatch SJ. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004; 4: 28-34.
104. Lage M and Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 2004; 14: 575-581.
105. Pelham WE, Gnagy EM, Burrows-McLean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Paediatr 2001; 107: E105.
106. Dopfner M, Gerber WD, Bonaschewski T, et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-twice-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004; 13(Suppl 1):193-201.
107. Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry 2004; 65: 1520-1524.
108. Feldman H, Crumrine P, Handen BL, Alvin R, Teodori J. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Children 1989; 143(a):1081-1086.
109. Seneky Y, Lobel D, Diamond GW, Weitz R, Inbar D. Isolated orofacial dyskinesia: a methylphenidate-induced movement disorder. Paediatr Neurol 2002; 27: 224-226.
110. Schwartz RH and Rushton HG. Stuttering priapism associated with withdrawal from sustained-release methylphenidate. J Paediatr 2004; 144: 675-676.
111. Joint Committee. In: British National Formulary London. British Med Association, 2005, pp. 206-207.
112. Hechtman L and Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-tern outcome. Paediatric Drugs 2003; 5: 787-794.
113. Sadeghian H. Lacunar stroke associated with methylphenidate abuse. Can J Neurol Sci 2004; 31: 109-111.
114. Schteinschnaider A, Plaghos LL, Garbugino S, et al. Cerebral arteritis following methylphenidate use. J Child Neurol 2000; 15: 265-267.
115. Leonhard C, Reif A, Beck M, Jacob C, Lesch KP. Reversible ischemic deficit associated with short-term methylphenidate medication. Int J Neuropsychopharmacol 2005; Epub ahead of print.
116. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2005; 66: 253-259.
117. Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side-effects. Clin Psychol Rev 2002; 22: 1107-1131.
118. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry 2001; 40: 525-529.
119. Coetzee M, Kaminer Y, Morales A. Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder. Substance Abuse 2002; 23: 165-169.
120. Varley CK, Vincent J, Varley P, Calderon R. Emergence of tics in children with attention deficit hyperactive disorder treated with stimulant medications. Comp Psychiatry 2001; 42: 228-233.
121. Kurlan R. Tourette's syndrome: are stimulants safe? Curr Neurol Neurosci Rep 2003; 3: 285-288.
122. Carlson GA, Kelly KL. Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol 2003; 13: 137-142.
123. Marbins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, Rohde LA. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 2004; 14: 195-206.
124. Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child an Adolesc Psychiatry 2001; 40: 188-196.
125. Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a re-analysis using drug-placebo and drug-drug response curve methodology. J Child Adolesc Psychopharmacol 2001; 11: 171-180.
126. Greevich S. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Exp Opin Invest Drugs 2001; 10: 2003-2011.
127. Faraone SV, Biederman J. Efficacy of Adderall for Attention-Deficit/ Hyperactivity Disorder: a meta-analysis. J Atten Disord 2002; 6: 69-75.
128. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ. Dextroamphetamine. Its cognitive and behavioural effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 1980; 37: 933-943.
129. Rapoport JL, Buchsbaum MS, Zahn TP, Weingartner H, Ludlow C, Mikkelsen EJ. Dextroamphetamine: cognitive and behavioural effects in normal prepubertal boys. Sci 1978; 199: 560-563.
130. Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z. A randomized, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 2000; 34: 874-875.
131. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001; 58: 775-782.
132. Horrigan JP, Barnhill CJ. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. J Clin Psychiatry 2000; 61: 414-417.
133. Ricaurte GA, Mechan AO, Yuan J, et al. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Experiential Ther 2005; 315: 91-98.
134. Glaser PE, Thomas TC, Joyce BM, Castellanos FX, Gerhardt GA. Differential effects of amphetamine isomers on dopamine release in time rat striatum and nucleus accumbens core. Psychopharmacol (Berl) 2005; 178: 250-258.
135. Morgan JC, Winter WC, Wooten GF. Amphetamine-induced chorea in attention deficit-hyperactivity disorder. Movement 2004; 19: 840-842.
136. Sachdev PS, Trollor JN. How high a dose of stimulant medication in adult attention deficit hyperactivity disorder? Aust N Z J Psychiatry 2000; 34: 645-650.
137. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther 2003; 25: 3065-3083.
138. Pliszka SR. The neuropsychopharmacology of attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005; 57: 1385-1390.
139. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized placebo-controlled studies. Biol Psychiatry 2003; 531: 12-120.
140. Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 2004; 24: 1020-1036.
141. Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Exp Opin Pharmacother 2003; 4: 1165-1174.
142. Micholson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment of children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896-1901.
143. Wernicke JF, Kratochvil CJ. Safety profile of Atomoxetine in the Treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63(Suppl 12): 50-55.
144. Simpson D, Plosker GC. Atomoxetine: a review of its use in adults with attention deficit hyperactive disorder. Drugs 2004; 64: 205-222.
145. Faraone SV, Biederman J, Spencer T, et al. Atomoxetine and stoop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005; 15: 664-670.
146. Reimherr FW, Merchant BK, Strang RE, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 2005; 58: 125-31.
147. Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 2005; 66: 294-299.
148. Chalon SA, Desager JP, Desante KA, et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacology Ther 2003; 73: 3-63.
149. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003; 13: 3-63.
150. Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol.
151. Bostic JQ, Biederman J, Spencer TJ, et al. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial. J Child Adolesc Psychopharmacol 200; 10: 05-216.
152. Bazire S. In: Psychotropic Drug Directory 1999, Salisbury UK, Mark Allen Publishing Ltd. 1999; 17-18.
153. Popper CW. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9: 05-646.
154. Prince JB, Wilens TE, Biedermann J, et al. A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2000; 10: 93-204.
155. Spencer T, Biederman J, Wilens T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin N Am 2004; 27: 73-383.
156. Satel S, Southwick S, Denta C. Use of Imipramine for Attention Deficit Disorder in a Borderline Patient. J Nerv Ment Dis 1988; 176: 305-309.
157. Wilens TE, Biederman J, Prince J, et al. Six-week, Double-Blind, Placebo-Controlled Study of Desipramine for Adult Attention Deficit Hyperactive Disorder. Am J Psychiatry 1996; 153:1147-1153.
158. Maidment ID. The use of antidepressants to treat attention deficit hyperactivity disorder in adults. J Psychopharmacol 2003; 17: 332-336.
159. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in Adults with Attention-Deficit/Hyperactivity Disorder: An Open Clin Trial. J Clin Psychiatry 1996; 57: 184-189.
160. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulants medicine in children with ADHD, other disruption behaviour disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 2004; 14: 243-254.
161. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001; 40: 753-772.
162. Taylor FB and Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2001; 21: 223-228.
163. Kessler RC, Adler L, Ames M et al. The World Health Organisation adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005; 35: 245-256.
164. Hazell PL and Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003; 42: 886-894.
165. Rugino TA and Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry 2001; 40: 230-235.
166. Taylor FB and Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000; 10: 311-320.
167. Turner DC, Clark L, Dowson JH, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention-deficit hyperactivity disorder. Biol Psychiatry 2004; 55: 1031-1040.
168. Rugino TA and Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. Pediatr Neurol 2003; 29: 136-142.
169. Turner DC, Robbins TW, Clark L, Aron AR, Dowson JH, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacol (Berl) 2003; 165: 260-269.
170. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of Buproprion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158: 282-288.
171. Kuperman S, Perry PJ, Gaffney GR et al. Buproprion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001; 13: 129-134.
172. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. Buproprion sustained-release in adolescents with comorbid attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2001; 40: 307-314.
173. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005; 57: 793-801.
174. Spender TJ. ADHD treatment across the life cycle. J Clin Psychiatry 2004; 65(Suppl 2): 22-26.
175. Dorrego MF, Canevaro L, Kuzic G, Sobe L, Starkstein SE. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. J Neuropsychiatry Clin Neurosci 2002; 14: 289-295.
176. Wilens TE, Biederman J, Wong J, Spencer TJ, Prince JB. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol 2000; 10: 217-222.
177. Adler LA and Chua HC. Management of ADHD in adults. J Clin Psychiatry 2002; 63(Suppl 12):29-35.
178. Ryback R and Ryback L. Gabapentin for behavioral dyscontrol. Am J Psychiatry 1995; 152: 1399.
179. Brown TE. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol 2004; 14: 129-136.
180. Kratochvil CJ, Newcom JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005; 44: 915-924.
181. Clark DB, Cornelius J, Wood DS, Vanyukov M. Psychopathology risk transmission in children of parents with substance use disorders. Am J Psychiatry 2004; 161: 685-691.
182. Johann M, Bobbe G, Putzhammer A, Wodarz N. Comorbidity of alcohol dependence with attention-deficit hyperactivity disorder: difference in phenotype with increased severity of the substance disorder, but not in genotype. Alcohol Clin Exp Res 2003; 27: 1527-1534.
183. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652-1658.
184. Gittelman R, Manuzzsa S, Shenker R, Bonagura N. Hyperactive boys almost grown up. Arch Gen Psychiatry 1985; 42: 937-947.
185. Manuzza S, Klein RG, Bessler A, Malloy P, La Padula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998; 155: 493-498.
186. Disney ER, Elkins IJ, McGue M, Iacuno WG. Effects of ADHD, conduct disorder, and gender on substance use and abuse in adolescence. Am J Psychiatry 1999; 156: 1515-1521.
187. Lynskey MT and Hall W. Attention deficit hyperactivity disorder and substance use disorder: is there a causal link? Addict 2001; 96: 815-822.
188. Flory K, Milich R, Lynam DR, Leukefeld C, Clayton R. Relations between childhood disruptive behaviour disorder and substance use and dependence symptoms in young adulthood. Psychol Addict Behaviour 2003; 17: 151-158.
189. Flory K, Lynam DR. The relations between attention deficit hyperactivity disorder and substance abuse: what role does conduct disorder play? Clin Child Fam Psychol Rev.
190. Wilens TE, Spencer TJ, Biederman J. Are attention-deficit hyperactivity disorder and the psychoactive substance use disorder really related? Harvard Rev Psychiatry 1995; 3: 160-163.
191. Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000; 61: 244-3251.
192. Levin FR, Evans SM, Kleber HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Dependence 1998; 52: 15-25.
193. Sullivan MA and Rudnik-Levin F. Attention-deficit/hyperactivity disorder and substance abuse. Ann N Y Acad Sci 2001; 931: 251-270.
194. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analysis review of the literature. Pediatr 2003; 111: 179-185.
195. Barkley RA, Fischer M, Snallish L, Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatr 2003; 111: 97-109.
196. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse. J Clin Psychiatry 2003; 64(Suppl 11): 3-8.
197. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry 2004; 65(Suppl 3):38-45.
198. Riggs PD, Leon SL, Mitulich SK, Pottle LC. An open trial of buproprion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998; 37: 1271-1278.
199. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Buproprion treatment for cocaine abuse and adult attention deficit/hyperactivity disorder. J Addict Disord 2002; 21: 1-16.
200. Solhkhah R, Wilens TE. Pharmacotherapy of adolescent alcohol and other drug use disorder. Alcohol Health Res World 1998; 22: 122-125.
201. Somoza EC, Winhusen TM, Bridge TP, et al. An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. J Addict Disorder 2004; 23: 77-92.
202. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998; 59: 300-305.
203. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10: 286-294.
204. Castaneda R, Sussman N, Levy K, Trujillo M. A treatment algorithm for attention deficit hyperactivity disorder in cocaine-dependent adults: a one-year private practice study with long-acting stimulants, fluoxetine and buproprion. Substance Abuse 1999; 20: 59-71.
205. Mattes JA. Propanolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol 1986; 6: 299-302.
206. Rey JM and Sawyer MG. Are psychostimulants being used appropriately to treat child and adolescent disorder? Br J Psychiatry 2002; 183: 173-174.
207. Sokal MS, Gray NS, Goldstein A, Kaye WH. Methylphenidate treatment for bulimia nervosa associated with cluster B personality disorder. Int J Eat Disord 1999; 25: 233-237.
208. Stringer AY, Josef NC. Methylphenidate in the treatment of aggression in two patients with antisocial personality disorder. Am J Psychiatry 1983; 140: 1365-1366.
209. Quintona H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25: 283-294.
210. Gross-Tsur V, Shalev RS, Badihi N, Manor O. Efficacy of methylphenidate in patients with cerebral palsy and attention-deficit hyperactivity disorder (ADHD). J Child Neurol 2002; 17: 863-866.
211. Amar MG and Buican B, Arnold LE. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies. J Child Adolesc Psychopharmacol 2003; 13: 29-40.
212. Jin C and Schachar R. Methylphenidate treatment of attention-deficit/ hyperactivity disorder secondary to traumatic brain injury: a critical appraisal of treatment studies. CNS Spectra 2004; 9: 217-226.
213. Whyte J, Hart T, Vaccaro M, et al. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Physical Med Rehabil 2004; 83:401-420.
214. Fleminger S, Greenwood RJ, Oliver DC. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev 2003; 1: CD003299.